Study identifier:D9612L00076
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Development of an Algorithm for Identification of Responders to Short Term Treatment with Esomeprazole (Nexium) in Primary Care
GERD
Phase 4
No
Esomeprazole
All
1000
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Diagnostic
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.
Location
Location
AABENRAA, Denmark
Location
AALBORG, Denmark
Location
ALBEK, Denmark
Location
ALBORG, Denmark
Location
ANS BY, Denmark
Location
ARHUS C, Denmark
Location
BAGSVERD, Denmark
Location
BIRKEROD, Denmark
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.